Updated Jul 16, 2026
Froimson Mark has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $11K.
Mark Froimson is a corporate executive and director known for his role at Pacira BioSciences, Inc., a biopharmaceutical company focused on non-opioid pain management solutions. He has a background in the pharmaceutical industry and has held various leadership positions in other companies.
| Role | Director |
|---|---|
| Notability | 60/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-13 | PCRX | Pacira BioSciences, Inc. | A — Grant or award | 6.4K | $0.00 | |
| 2026-03-19 | PCRX | Pacira BioSciences, Inc. | S — Open-market sale | 500 | $21.81 | $11K |
Mark Froimson is a corporate executive and director known for his role at Pacira BioSciences, Inc., a biopharmaceutical company focused on non-opioid pain management solutions. He has a background in the pharmaceutical industry and has held various leadership positions in other companies.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($11K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Froimson Mark profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.